ArticleBMJ public health2025
Impact of the resumption of proactive recommendation of HPV vaccination on HPV vaccination rates in Japan: an interrupted time series analysis based on the VENUS study.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Safety monitoring of bivalent, quadrivalent, and 9-valent human papillomavirus vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study.Human vaccines & immunotherapeutics · 2026Article
- Trends, disparities, and multilevel interventions: A global review of HPV vaccination among university students.Human vaccines & immunotherapeutics · 2026Review
- Knowledge of Syphilis and Human Papillomavirus and Associated Factors in a Japanese University Setting: A Cross-Sectional Study.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Human papillomavirus (HPV) vaccination coverage in Japan is among the lowest worldwide (<1% in 2019). In April 2022, the Japanese government resumed proactive recommendations for routine HPV vaccination after an 8-year suspension and initiated a catch-up vaccination programme. This study aimed to assess the impact of this change in the vaccination policy on HPV vaccination rates in Japan. Methods: We used data from the resident and vaccination registries of one municipality in Japan collected from January 2019 to June 2023. We estimated the cumulative vaccination rates for each female cohort born in the 2003-2011 fiscal years (FYs, 1 April-31 March). We also assessed the impact of the change in governmental policy by estimating the changes in the level and trend of first vaccination rates among girls eligible for routine vaccination using a segmented Poisson regression with an interrupted time series (ITS) design. Results: We identified 13 376 girls eligible for routine HPV vaccination (born between FY2003 and FY2011) during the study period. The FY2006 birth cohort had the highest cumulative vaccination rates for the first, second and third doses in June 2023 (33.6%, 30.2% and 27.0%, respectively). The ITS analysis shows that the level change was 1.53 (95% CI 1.24 to 1.91), which means that the first vaccination rate increased by 53% in April 2022. The trend change was 0.97 (95% CI 0.95 to 1.00), indicating that the trend of the first HPV vaccination remained almost unchanged before and after April 2022. Conclusions: The resumption of the proactive recommendation of HPV vaccination by the Japanese government promoted HPV vaccinations. However, the changes in HPV vaccination rates and trends remain insufficient when compared with the WHO's target of achieving 90% full vaccination coverage among girls by age 15 years. Additional efforts are required to encourage and promote vaccination in the Japanese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.